We wanted to make you aware of FDA legislation going into effect on March 23, 2020 regarding availability of hCG and what you can do to make your voice heard.There is a great deal of misinformation circulating on the Internet, so we wanted to clarify for our patients.
It is important to note that our pharmacy provider does not anticipate discontinuing hCG without further clarification from the FDA. We do not anticipate any disruption in our ability to source this medication for our patients. However, we expect that many other compounding pharmacies, clinics and patients will be negatively impacted. Read more for details.
What is happening with HCG
This change actually happened 10 years ago under the Biologics Price Competition and Innovation Act of 2009 (BPCIA) and takes effect March 23, 2020. The FDA did not take compounding into consideration, so there was no commenting period to be able to oppose it at that time.
We do not believe it was the intention of the FDA to harm the compounding industry by properly classifying HCG. We are waiting on clarification from the FDA to allow an exception for compounding pharmacies to continue to produce "transitional biologics". Transitional biologics include substances that were previously pharmaceuticals but are now reclassified as biologics. HCG and insulin are the primary drugs everyone is focusing on.
What will happen on March 23rd
Many compounding pharmacies will be forced to discontinue compounding all products containing HCG without further clarification from the FDA. During this time, compounded HCG and FSH will still be available through an FDA registered outsourcing facility that compounds under cGMP quality controls. (Defy Medical's pharmacy partners meet this high standard.)
We believe the FDA will allow the exception but only for pharmacies who are following cGMP since HCG requires a specific environment and testing methodology to guarantee quality.
What's Can YOU DO to help?
This law was not established to limit access or be anti-compounding, but to expand access and lower pricing. Our pharmacy partners are exploring lobbying options to support a legislative change to the DQSA to provide permanent statutory access to transition biologics for compounding and to gain clarity on this immediate concern.
We are confident there will be a positive long-term resolution but YOUR ACTION NOW can help make that a reality.
TIPS FOR SUBMITTING EFFECTIVE COMMENTS to the FDA
DEADLINE: February 15, 2020
|